Modality
Degrader
MOA
TYK2i
Target
LAG-3
Pathway
Apoptosis
ThymomaPVNMOSD
Development Pipeline
Preclinical
~Mar 2011
→ ~Jun 2012
Phase 1
~Sep 2012
→ ~Dec 2013
Phase 2
~Mar 2014
→ ~Jun 2015
Phase 3
~Sep 2015
→ ~Dec 2016
NDA/BLA
~Mar 2017
→ ~Jun 2018
Approved
Sep 2018
→ Dec 2029
ApprovedCurrent
NCT05326905
1,200 pts·Thymoma
2021-06→2029-12·Active
NCT04886343
1,607 pts·NMOSD
2019-11→TBD·Active
NCT05080344
1,488 pts·PV
2020-10→2029-11·Completed
+1 more trial
6,919 total pts3 indications
CompletedCurrentUpcoming
Catalysts (3)
2029-05-163.1y awayPh3 Readout· PV
2029-11-133.6y awayPh3 Readout· PV
2029-12-193.7y awayPh3 Readout· Thymoma
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
Approved
Active
Approved
Active
Approved
Complet…
Approved
Active
Catalysts
Ph3 Readout
2029-05-16 · 3.1y away
PV
Ph3 Readout
2029-11-13 · 3.6y away
PV
Ph3 Readout
2029-12-19 · 3.7y away
Thymoma
ActiveCompleted|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05326905 | Approved | Thymoma | Active | 1200 | SeizFreq |
| NCT04886343 | Approved | NMOSD | Active | 1607 | Biomarker |
| NCT05080344 | Approved | PV | Completed | 1488 | VA |
| NCT06541873 | Approved | PV | Active | 2624 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| Sotorapivir | Moderna | Approved | FLT3 |